Massimiliano Colao
Keine laufenden Positionen mehr
Profil
Massimiliano Colao formerly worked at Amgen, Inc., as Vice President-Inflammation Sales, Abeona Therapeutics, Inc., as Chief Commercial Officer from 2018 to 2020, Alexion Pharmaceuticals, Inc., as Senior Vice President-US Commercial Operations from 2014 to 2017, and Aurinia Pharmaceuticals, Inc., as Chief Commercial Officer from 2020 to 2022.
Mr. Colao received his Masters Business Admin degree from the University of Southern California and undergraduate degree from the University of California, Los Angeles.
Ehemalige bekannte Positionen von Massimiliano Colao
| Unternehmen | Position | Ende |
|---|---|---|
| AURINIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 15.07.2022 |
| ABEONA THERAPEUTICS INC. | Corporate Officer/Principal | 01.01.2020 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2017 |
| AMGEN INC. | Corporate Officer/Principal | 01.01.2013 |
Ausbildung von Massimiliano Colao
| University of Southern California | Masters Business Admin |
| University of California, Los Angeles | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| ABEONA THERAPEUTICS INC. | Health Technology |
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
